Cassava Sciences Inc vs Mizuho Financial Group Inc. Sponosred ADR (Japan) — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $10.58 (market cap $132.18B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 3354.8× Cassava Sciences Inc's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.7% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Mizuho Financial Group Inc. Sponosred ADR (Japan) for 0 Days on average.
| FLNA | MFG | |
|---|---|---|
Market Cap | $39.40M | $132.18B |
Volume | 759,018 | 3,264,662 |
Sector | Health | Financials |
52-Week High | $4.64 | $11.45 |
52-Week Low | $0.68 | $6.09 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | -$43.28M | $35.48T |
Dividend Yield | — | 1.7% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.
Read more on MFG →